Protalix BioTherapeutics (PLX) Aperçu de l'action
Protalix BioTherapeutics, Inc. est une société biopharmaceutique qui se consacre au développement, à la production et à la commercialisation de protéines thérapeutiques recombinantes basées sur le système d'expression de protéines à partir de cellules végétales ProCellEx. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 0/6 |
| Performances passées | 6/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
PLX Community Fair Values
Create NarrativeSee what 57 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$4.23
FV
45.2% sous-évalué décote intrinsèque14.00%
Revenue growth p.a.
346
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
Protalix BioTherapeutics, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$2.32 |
| Plus haut sur 52 semaines | US$3.19 |
| Plus bas sur 52 semaines | US$1.36 |
| Bêta | -0.0024 |
| Variation sur 1 mois | 16.58% |
| Variation sur 3 mois | 5.94% |
| Variation sur 1 an | 57.82% |
| Variation sur 3 ans | 24.73% |
| Variation sur 5 ans | 35.67% |
| Évolution depuis l'introduction en bourse | -99.15% |
Nouvelles et mises à jour récentes
Mise à jour du récit • Jun 25
PLX: Maintained Fair Value And 2026 Revenue Mix Will Support Upside
Analysts have maintained their fair value estimate for Protalix BioTherapeutics at $11.00, making only slight adjustments to the discount rate and long-term assumptions that leave the overall price target effectively unchanged. What's in the News Protalix BioTherapeutics reaffirmed its total revenue guidance for 2026 in the range of approximately US$78.0 million to US$83.0 million, according to a recent corporate guidance update.Mise à jour du récit • Jun 05
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Analysts have kept their $11.00 price target for Protalix BioTherapeutics unchanged, citing a mix of softer revenue growth and profit margin expectations, along with a very large projected future P/E multiple that offsets only modest tweaks to the discount rate in their models. What's in the News Protalix BioTherapeutics reaffirmed its 2026 total revenue guidance, projecting US$78.0 million to US$83.0 million, which includes a US$25.0 million milestone payment already received from Chiesi.Mise à jour du récit • May 11
PLX: Extended Dosing Approval And 2026 Outlook Will Support Further Upside
Analysts kept their $11.00 price target on Protalix BioTherapeutics unchanged, citing only minor adjustments in discount rate, revenue growth, profit margin, and future P/E assumptions that did not materially alter their overall view of the stock. What's in the News The European Commission approved a 2 mg/kg every 4 weeks dosing regimen for pegunigalsidase alfa (Elfabrio) in adults with Fabry disease who are stable on enzyme replacement therapy, extending the infusion interval from every 2 weeks to every 4 weeks (Key Developments).Recent updates
Mise à jour du récit • Jun 25
PLX: Maintained Fair Value And 2026 Revenue Mix Will Support Upside
Analysts have maintained their fair value estimate for Protalix BioTherapeutics at $11.00, making only slight adjustments to the discount rate and long-term assumptions that leave the overall price target effectively unchanged. What's in the News Protalix BioTherapeutics reaffirmed its total revenue guidance for 2026 in the range of approximately US$78.0 million to US$83.0 million, according to a recent corporate guidance update.Mise à jour du récit • Jun 05
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Analysts have kept their $11.00 price target for Protalix BioTherapeutics unchanged, citing a mix of softer revenue growth and profit margin expectations, along with a very large projected future P/E multiple that offsets only modest tweaks to the discount rate in their models. What's in the News Protalix BioTherapeutics reaffirmed its 2026 total revenue guidance, projecting US$78.0 million to US$83.0 million, which includes a US$25.0 million milestone payment already received from Chiesi.Mise à jour du récit • May 11
PLX: Extended Dosing Approval And 2026 Outlook Will Support Further Upside
Analysts kept their $11.00 price target on Protalix BioTherapeutics unchanged, citing only minor adjustments in discount rate, revenue growth, profit margin, and future P/E assumptions that did not materially alter their overall view of the stock. What's in the News The European Commission approved a 2 mg/kg every 4 weeks dosing regimen for pegunigalsidase alfa (Elfabrio) in adults with Fabry disease who are stable on enzyme replacement therapy, extending the infusion interval from every 2 weeks to every 4 weeks (Key Developments).Mise à jour du récit • Apr 26
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Analysts now set Protalix BioTherapeutics' price target at $11.00. The unchanged level reflects only minimal tweaks to inputs such as the discount rate, long term revenue growth, profit margin assumptions and future P/E expectations.Mise à jour du récit • Apr 09
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Analysts have maintained their $11.00 price target for Protalix BioTherapeutics, citing relatively stable assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the basis for keeping their outlook unchanged. What's in the News The European Commission approves a 2 mg/kg every four weeks dosing regimen for pegunigalsidase alfa in adults with Fabry disease who are stable on enzyme replacement therapy, extending the infusion interval from every two weeks to every four weeks (Key Developments).Mise à jour du récit • Mar 26
PLX: New Dosing Approval And 2026 Outlook Will Support Undervalued Upside
Analysts kept their $11.00 price target on Protalix BioTherapeutics unchanged, highlighting revised assumptions for revenue growth, profit margins, the discount rate and future P/E as key drivers behind their updated model. What's in the News Protalix BioTherapeutics issued 2026 total revenue guidance of approximately $78.0 million to $83.0 million, which includes a $25.0 million milestone payment from Chiesi tied to regulatory progress for Elfabrio (company guidance).Mise à jour du récit • Mar 09
PLX: Extended Fabry Dosing Will Support Undervalued Long Term Outlook
Analysts have reiterated an $11.00 price target for Protalix BioTherapeutics, citing only slight tweaks to model inputs such as the discount rate, long-term revenue growth, profit margins, and future P/E assumptions rather than any major shift in their overall view. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics reported that the European Medicines Agency's Committee for Medicinal Product for Human Use issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen of pegunigalsidase alfa for adult Fabry patients who are stable on enzyme replacement therapy (Key Developments).Mise à jour du récit • Feb 23
PLX: Fabry Dosing Extension Will Support Undervalued Long Term Outlook
Analysts are maintaining their $11.00 price target for Protalix BioTherapeutics while slightly refining core modeling inputs such as the discount rate, long term revenue growth, profit margin and future P/E assumptions to better align with their updated risk and earnings outlook. What's in the News CHMP of the EMA issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen for pegunigalsidase alfa in adult Fabry disease patients who are stable on enzyme replacement therapy, potentially giving eligible patients a longer interval between infusions (Product related announcement).Mise à jour du récit • Feb 08
PLX: Renal ASO Pipeline And Fabry Dosing Expansion Will Drive Upside
Analysts have maintained their price target for Protalix BioTherapeutics at US$11.00, citing a combination of updated assumptions regarding the discount rate, revenue growth, profit margins, and a higher future P/E multiple as reasons to keep their existing valuation view. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics reported that the EMA's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen of pegunigalsidase alfa for adult Fabry patients who are stable on enzyme replacement therapy, aiming to extend time between infusions so patients can focus more on daily life (Key Developments).Mise à jour du récit • Jan 24
PLX: Renal ASO Collaboration Will Drive Next Phase Of Upside Potential
Analysts have maintained their US$11.00 price target for Protalix BioTherapeutics, citing only slight adjustments to their discount rate, long term revenue growth, profit margin assumptions and future P/E outlook, rather than any major shift in their thesis. What's in the News Protalix BioTherapeutics and Secarna Pharmaceuticals entered a collaboration and option agreement to discover antisense oligonucleotide therapies targeting rare renal indications, with Secarna using its OligoCreator platform to design and profile candidates and Protalix selecting the biological targets (Key Developments).Mise à jour du récit • Jan 10
PLX: Renal Collaboration Agreement Will Drive Next Phase Of Upside Potential
Analysts have maintained their fair value estimate for Protalix BioTherapeutics at US$11.00. This reflects only minor adjustments to assumptions around discount rate, revenue growth, profit margins and future P/E that do not materially change their overall view.Mise à jour du récit • Dec 16
PLX: European Label Expansion Review Will Drive Next Phase Of Upside Potential
Analysts have nudged their price target on Protalix BioTherapeutics slightly higher to $11.00, reflecting marginal adjustments to discount rate, long term growth, and profitability assumptions, while maintaining a broadly consistent valuation framework. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics requested re examination of the EMA CHMP negative opinion on adding a once every 4 weeks 2 mg/kg Elfabrio dosing regimen to the currently approved every 2 weeks regimen, seeking broader label flexibility in Europe (Key Developments) Safety data from Elfabrio clinical trials highlighted hypersensitivity reactions in 14 percent of treated patients and anaphylaxis in 3 percent, underscoring the need for careful infusion monitoring and potential dose adjustments (Key Developments) Additional clinical observations included infusion associated reactions in 29 percent of Elfabrio patients and a reported case of membranoproliferative glomerulonephritis, prompting recommendations to monitor renal function and infusion related symptoms (Key Developments) Protalix BioTherapeutics was added to the S&P Global BMI Index, potentially increasing its visibility and accessibility to global institutional investors (Key Developments) Valuation Changes Fair value estimate maintained at $11.00 per share, indicating no change to the analyst target price.Mise à jour du récit • Dec 02
PLX: European Regulatory Review Will Unlock Next Phase Of Upside Potential
Analysts have lowered their price target for Protalix BioTherapeutics from $12.50 to $11.00, citing a slight reduction in expected revenue growth and profit margins. What's in the News Protalix BioTherapeutics and Chiesi Global Rare Diseases have requested a re-examination of the negative opinion by the European Medicines Agency regarding the new dosing regimen for Elfabrio.Mise à jour du récit • Nov 18
PLX: European Review Process Will Drive Next Phase Of Momentum
Analysts have lowered their price target for Protalix BioTherapeutics from $14.00 to $12.50. They cite more conservative expectations regarding revenue growth and profit margins.
Nouveau récit • May 19
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
As of right now the stock as a current yield of about 2.42%, with a return on equity of about 6.79%. So a bit off of my goals of at least 5% and 10%. However over the last 3 years revenue has grown on
Nouveau récit • Apr 29
PRX-115 Trials And Elfabrio Launch Will Open Future Markets
Successful Phase II trials and Chiesi's involvement with Elfabrio could drive growth through new marketable products and increased market adoption.Article d’analyse • Feb 22
Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon
We feel now is a pretty good time to analyse Protalix BioTherapeutics, Inc.'s ( NYSEMKT:PLX ) business as it appears...Article d’analyse • Jan 14
Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...Article d’analyse • Dec 10
Could The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Ownership Structure Tell Us Something Useful?
A look at the shareholders of Protalix BioTherapeutics, Inc. ( NYSEMKT:PLX ) can tell us which group is most powerful...Rendement pour les actionnaires
| PLX | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | -1.3% | 4.1% | 1.6% |
| 1Y | 57.8% | 41.1% | 18.6% |
Rendement vs Industrie: PLX a dépassé le secteur US Biotechs qui a rapporté 41.1 % au cours de l'année écoulée.
Rendement vs marché: PLX a dépassé le marché US qui a rapporté 18.6 % au cours de l'année écoulée.
Volatilité des prix
| PLX volatility | |
|---|---|
| PLX Average Weekly Movement | 5.9% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: PLX n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de PLX ( 6% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| n/a | 226 | Dror Bashan | www.protalix.com |
Protalix BioTherapeutics, Inc. est une société biopharmaceutique qui se consacre au développement, à la production et à la commercialisation de protéines thérapeutiques recombinantes basées sur le système d'expression de protéines à base de cellules végétales ProCellEx. La société fournit Elelyso pour le traitement de la maladie de Gaucher et Elfabrio pour le traitement des patients adultes dont le diagnostic de la maladie de Fabry a été confirmé. Elle développe également PRX-115, une uricase recombinante PEGylée exprimée par des cellules végétales, qui est en essai de phase 2 pour le traitement de la goutte, et PRX-119, une DNase I humaine recombinante PEGylée exprimée par des cellules végétales, un produit candidat pour le traitement des maladies des pièges extracellulaires des neutrophiles.
Protalix BioTherapeutics, Inc. Résumé des fondamentaux
| PLX statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$186.93m |
| Bénéfices(TTM) | US$15.33m |
| Recettes(TTM) | US$76.38m |
12.2x
Ratio P/E2.4x
Ratio P/SLe site PLX est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| PLX compte de résultat (TTM) | |
|---|---|
| Recettes | US$76.38m |
| Coût des recettes | US$41.83m |
| Marge brute | US$34.55m |
| Autres dépenses | US$19.22m |
| Les revenus | US$15.33m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 0.19 |
| Marge brute | 45.24% |
| Marge bénéficiaire nette | 20.07% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de PLX?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/06 20:13 |
| Cours de l'action en fin de journée | 2026/07/02 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Protalix BioTherapeutics, Inc. est couverte par 8 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Ritu Baral | Canaccord Genuity |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Peter Welford | Jefferies LLC |